Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) from NORSE 1

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access